ArticleResearch square2025
DrugReX: an explainable drug repurposing system powered by large language models and literature-based knowledge graph.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repurposing offers a time-efficient and cost-effective approach for therapeutic development by finding new uses for existing drugs. Additionally, achieving explainability in drug repurposing remains a challenge due to the lack of transparency in decision-making processes, hindering researchers' understanding and trust in the generated insights. To address these issues, we present DrugReX, a system integrating a literature-based knowledge graph, embedding, scoring system, and explanation modules using large language models (LLMs). We validated DrugReX on 15 established drug repurposing cases, achieving significantly high scores. As a real-world use case, we applied DrugReX to identify candidate drugs for Alzheimer's disease and related dementias (ADRD) and thoroughly evaluated the pipeline. The system identified 25 promising candidates, with nine clustering with FDA-approved ADRD drugs and 10 linked to ongoing clinical trials. For explainability, an LLM was employed to generate explanations supported by evidence from the literature-based knowledge graph. Domain expert evaluation revealed that DrugReX-produced explanations were superior in quality and clarity than using an LLM alone, enhancing the explainability of repurposing predictions. This study represents the first integration of LLMs to provide explainable insights into drug repurposing, bridging computation precision with explainability, and thus, ultimately enabling more transparent and reliable decision-making in therapeutic development.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.